Duyuru • Jun 28
Dermapharm Holding Se Confirms Earnings Guidance for 2026 Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million. Duyuru • May 18
Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026 Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time. Duyuru • Apr 01
Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026 Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026. Duyuru • Mar 11
Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million. Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026. Duyuru • Jun 28
Dermapharm Holding SE Approves Annual Dividend Dermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution. Duyuru • May 16
Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025 Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time. Duyuru • Jan 02
Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025 Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025 Duyuru • May 09
Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024 Dermapharm Holding SE announced that they will report Q1, 2024 results on May 15, 2024 Duyuru • Mar 28
Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024 Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024. Duyuru • Mar 14
Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024 Dermapharm Holding SE announced that they will report fiscal year 2023 results on Mar 28, 2024 Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to €45.46, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €73.48 per share. Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: €2.49 (vs €3.89 in FY 2021) Full year 2022 results: EPS: €2.49 (down from €3.89 in FY 2021). Revenue: €1.04b (up 8.4% from FY 2021). Net income: €134.2m (down 36% from FY 2021). Profit margin: 13% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €36.74, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 14x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 2.6% over the past three years. Valuation Update With 7 Day Price Move • Nov 23
Investor sentiment improved over the past week After last week's 18% share price gain to €44.92, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 27% over the past three years. Reported Earnings • Nov 18
Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021) Third quarter 2022 results: EPS: €0.98 (down from €1.15 in 3Q 2021). Revenue: €277.8m (up 13% from 3Q 2021). Net income: €52.5m (down 15% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 17
Investor sentiment deteriorated over the past week After last week's 22% share price decline to €37.52, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years. Reported Earnings • Sep 09
Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021) Second quarter 2022 results: EPS: €0.27 (down from €0.74 in 2Q 2021). Revenue: €246.2m (up 12% from 2Q 2021). Net income: €14.5m (down 64% from 2Q 2021). Profit margin: 5.9% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 6.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 26
Upcoming dividend of €2.17 per share Eligible shareholders must have bought the stock before 02 June 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 4.6%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%). Reported Earnings • May 19
First quarter 2022 earnings released: EPS: €0.69 (vs €0.67 in 1Q 2021) First quarter 2022 results: EPS: €0.69 (up from €0.67 in 1Q 2021). Revenue: €239.1m (up 11% from 1Q 2021). Net income: €37.4m (up 2.9% from 1Q 2021). Profit margin: 16% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.8%, compared to a 5.3% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 14
Full year 2021 earnings released: EPS: €3.89 (vs €1.59 in FY 2020) Full year 2021 results: EPS: €3.89 (up from €1.59 in FY 2020). Revenue: €960.1m (up 19% from FY 2020). Net income: €209.6m (up 144% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 10%, compared to a 13% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €264.5m (up 31% from 3Q 2020). Net income: €61.8m (up 173% from 3Q 2020). Profit margin: 23% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Sep 08
Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €219.1m (up 16% from 2Q 2020). Net income: €39.8m (up 233% from 2Q 2020). Profit margin: 18% (up from 6.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Jun 17
Upcoming dividend of €0.88 per share Eligible shareholders must have bought the stock before 24 June 2021. Payment date: 28 June 2021. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (4.0%). Lower than average of industry peers (3.6%). Reported Earnings • May 21
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €218.0m (up 11% from 1Q 2020). Net income: €36.3m (up 36% from 1Q 2020). Profit margin: 17% (up from 14% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improved over the past week After last week's 21% share price gain to €74.65, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 24x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 89% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.84 per share. Reported Earnings • Apr 16
Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €820.5m (up 15% from FY 2019). Net income: €85.8m (up 11% from FY 2019). Profit margin: 11% (in line with FY 2019). Valuation Update With 7 Day Price Move • Mar 29
Investor sentiment improved over the past week After last week's 16% share price gain to €64.69, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 83% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.89 per share. Is New 90 Day High Low • Feb 05
New 90-day high: €60.89 The company is up 32% from its price of €46.10 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.45 per share. Is New 90 Day High Low • Dec 29
New 90-day high: €57.29 The company is up 26% from its price of €45.54 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.08 per share. Is New 90 Day High Low • Dec 01
New 90-day high: €55.96 The company is up 22% from its price of €45.82 on 02 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.89 per share.